Have a feature idea you'd love to see implemented?
Let us know!
IPSC Century Therapeutics Inc
Price (delayed)
$1.24
Market cap
$105.44M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.85
Enterprise value
$100.84M
Highlights
The revenue rose by 31% since the previous quarter and by 8% year-on-year
Century Therapeutics's gross profit has increased by 31% from the previous quarter and by 8% YoY
The quick ratio has increased by 21% year-on-year but it has declined by 2.5% since the previous quarter
The debt has grown by 12% year-on-year but it has declined by 3.6% since the previous quarter
The equity has declined by 12% since the previous quarter and by 11% year-on-year
Key stats
What are the main financial stats of IPSC
Market
Valuations
Earnings
Shares outstanding
85.03M
Market cap
$105.44M
Enterprise value
$100.84M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.54
Price to sales (P/S)
39.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.56
Revenue
$2.69M
EBIT
-$130.75M
EBITDA
-$116.8M
Free cash flow
-$113.1M
Per share
Balance sheet
Liquidity
EPS
-$1.85
Free cash flow per share
-$1.34
Book value per share
$2.31
Revenue per share
$0.03
TBVPS
$4.13
Total assets
$388.62M
Total liabilities
$192.93M
Debt
$50.84M
Equity
$195.69M
Working capital
$186.19M
Debt to equity
0.26
Current ratio
10.39
Quick ratio
10.14
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-4,350.1%
Gross margin
100%
Net margin
-4,837.7%
Operating margin
-5,386%
Return on assets
-34.3%
Return on equity
-66.6%
Return on invested capital
-38.4%
Return on capital employed
-35.5%
Return on sales
-4,869.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IPSC stock price
How has the Century Therapeutics stock price performed over time
Intraday
-1.59%
1 week
-1.59%
1 month
-19.48%
1 year
-10.79%
YTD
-62.65%
QTD
-27.49%
Financial performance
How have Century Therapeutics's revenue and profit performed over time
Revenue
$2.69M
Gross profit
$2.69M
Operating income
-$144.62M
Net income
-$129.89M
Gross margin
100%
Net margin
-4,837.7%
The revenue rose by 31% since the previous quarter and by 8% year-on-year
Century Therapeutics's gross profit has increased by 31% from the previous quarter and by 8% YoY
The net margin has grown by 25% since the previous quarter and by 7% year-on-year
Century Therapeutics's operating margin has increased by 24% QoQ
Growth
What is Century Therapeutics's growth rate over time
Valuation
What is Century Therapeutics stock price valuation
P/E
N/A
P/B
0.54
P/S
39.12
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.56
The EPS has increased by 16% year-on-year and by 9% since the previous quarter
IPSC's price to book (P/B) is 51% lower than its last 4 quarters average of 1.1
The equity has declined by 12% since the previous quarter and by 11% year-on-year
The price to sales (P/S) is 64% lower than the last 4 quarters average of 108.7
The revenue rose by 31% since the previous quarter and by 8% year-on-year
Efficiency
How efficient is Century Therapeutics business performance
Century Therapeutics's ROE has decreased by 35% YoY
The return on sales has increased by 24% since the previous quarter and by 3.2% year-on-year
The ROIC has contracted by 19% YoY and by 2.1% from the previous quarter
Century Therapeutics's return on assets has decreased by 17% YoY
Dividends
What is IPSC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IPSC.
Financial health
How did Century Therapeutics financials performed over time
Century Therapeutics's total assets is 101% higher than its total liabilities
The current ratio has grown by 22% YoY but it has contracted by 2.2% from the previous quarter
The quick ratio has increased by 21% year-on-year but it has declined by 2.5% since the previous quarter
The debt is 74% smaller than the equity
IPSC's debt to equity is up by 24% year-on-year and by 8% since the previous quarter
The equity has declined by 12% since the previous quarter and by 11% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.